Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

CRISPR Therapeutics (NASDAQ:CRSP) gains visibility as biotechnology activity aligns with broader movements across the Nasdaq ...

A rare disease mom and scientist shares on the "First Opinion Podcast" how she serves as a translator between her two ...

When UC Berkeley biochemist Jennifer Doudna first began studying how bacteria fight virus infections, she had no idea it ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Scientists grew a microscopic fungus into a more efficient — and meat-like — edible protein by tweaking just two genes with ...

Nearly three decades since the remarkable cloning of Dolly the sheep, it has all gone quiet on the human cloning front.

The outlook for dementia care is changing fast. UC experts explain what that means for patients and families, and what it ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based ...

Goldenberries taste like a cross between pineapple and mango, pack the nutritional punch of a superfood, and are increasingly ...

Spaceflight, genetic tinkering, and the psychological implications of technological acceleration are explored with accuracy ...

A Nobel laureate, he identified an enzyme that cuts DNA, laying the groundwork for milestones in scientific research and ...